BioCentury
ARTICLE | Clinical News

Quinolones/fluoroquinolones regulatory update

February 16, 2017 8:22 PM UTC

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a review of systemic and inhaled quinolone and fluoroquinolone antibiotics to evaluate the persistence of serious side effects primarily affecting muscles, joints and the nervous system. Germany’s Federal Institute for Drugs and Medical Devices (BfArM) requested the review following reports of long-lasting side effects associated with the use of such antibiotics. Quinolone and fluoroquinolone antibiotics are used to treat serious bacterial infections and include cinoxacin, ciprofloxacin, enoxacin, flumequine, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, pefloxacin, pipemidic acid, prulifloxacin and rufloxacin...

BCIQ Company Profiles

European Medicines Agency (EMA)